Gadolinium Enhanced MR Coronary Vessel Wall Imaging at 3.0 Tesla.

Details

Ressource 1Download: 20981285_BIB_17B5D22698AD.pdf (6245.43 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_17B5D22698AD
Type
Article: article from journal or magazin.
Collection
Publications
Title
Gadolinium Enhanced MR Coronary Vessel Wall Imaging at 3.0 Tesla.
Journal
Cardiology Research and Practice
Author(s)
Kelle S., Schlendorf K., Hirsch G.A., Gerstenblith G., Fleck E., Weiss R.G., Stuber M.
ISSN
2090-0597
Publication state
Published
Issued date
2010
Volume
2010
Pages
856418
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Purpose. We evaluated the influence of the time between low-dose gadolinium (Gd) contrast administration and coronary vessel wall enhancement (LGE) detected by 3T magnetic resonance imaging (MRI) in healthy subjects and patients with coronary artery disease (CAD). Materials and Methods. Four healthy subjects (4 men, mean age 29 ± 3 years and eleven CAD patients (6 women, mean age 61 ± 10 years) were studied on a commercial 3.0 Tesla (T) whole-body MR imaging system (Achieva 3.0 T; Philips, Best, The Netherlands). T1-weighted inversion-recovery coronary magnetic resonance imaging (MRI) was repeated up to 75 minutes after administration of low-dose Gadolinium (Gd) (0.1 mmol/kg Gd-DTPA). Results. LGE was seen in none of the healthy subjects, however in all of the CAD patients. In CAD patients, fifty-six of 62 (90.3%) segments showed LGE of the coronary artery vessel wall at time-interval 1 after contrast. At time-interval 2, 34 of 42 (81.0%) and at time-interval 3, 29 of 39 evaluable segments (74.4%) were enhanced. Conclusion. In this work, we demonstrate LGE of the coronary artery vessel wall using 3.0 T MRI after a single, low-dose Gd contrast injection in CAD patients but not in healthy subjects. In the majority of the evaluated coronary segments in CAD patients, LGE of the coronary vessel wall was already detectable 30-45 minutes after administration of the contrast agent.
Pubmed
Open Access
Yes
Create date
17/02/2011 11:13
Last modification date
09/08/2024 6:38
Usage data